You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Potential applications<br />
The use of therapeutic cancer vaccines still has to be fi rmly<br />
established and previous clinical trials strongly indicate that<br />
not all patients benefi t from receiving such treatment. The<br />
present study will allow us to establish whether the results of<br />
ENACT can be used in a clinical setting. The identifi cation of<br />
indicators of patient response to immunotherapy would<br />
allow clinicians to target vaccination to those patients who<br />
are most likely to respond. The fi ndings of the present study<br />
could result in assays that could be used to predict treatment<br />
outcome and/or monitor patients during the course of<br />
treatment. This would benefi t the health care industry and<br />
patient care and the fi ndings may be applicable to cancers<br />
other than those included in the research programme. The<br />
approach will allow us to gain further scientifi c understanding<br />
of the immune response to tumour antigens, which may<br />
infl uence the development of future generations of cancer<br />
vaccine. This research represents a valuable contribution to<br />
the welfare of patients who would be considered to be suitable<br />
candidates for vaccine-based therapy.<br />
Coordinator<br />
Robert Rees<br />
Interdisciplinary Biomedical<br />
<strong>Research</strong> Centre<br />
Nottingham Trent University<br />
Faculty of Science and Land-based Studies<br />
Nottingham, United Kingdom<br />
robert.rees@ntu.ac.uk<br />
Partners<br />
Elissaveta Naumova<br />
Laboratory of Clinical Immunology<br />
University Hospital<br />
Sofia, Bulgaria<br />
immun@medun.acad.bg<br />
Graham Pawelec<br />
Abt.Innere Medizin II Zentrum<br />
für Medizinische Forschung,<br />
ZMF Universitätsklinikum<br />
Tübingen, Germany<br />
graham.pawelec@uni-tuebingen.de<br />
TREATMENT<br />
Rolf Kiessling<br />
Dept. of Oncology-Pathology<br />
Karolinska Institute<br />
Stockholm, Sweden<br />
rolf.kiessling@mtc.ki.se<br />
Francine Jotereau<br />
INSERM U463, Institut de Biologie<br />
Nantes, France<br />
jotereau@nantes.inserm<br />
Piotr Laidler<br />
Institute of Medical Biochemistry<br />
Jagiellonian University<br />
Medical College<br />
Krakow, Poland<br />
mblaidle@cyf-kr.edu.pl<br />
Aija Line<br />
Biomedical <strong>Research</strong> Study Centre<br />
University of Latvia<br />
Riga, Latvia<br />
aija@biomed.lu.lv<br />
Federico Garrido<br />
Departamento de Analisis Clinicos<br />
Hospital Universitario<br />
Granada, Spain<br />
fgarrido@hvn.sas.junta-andalucia.es<br />
Dirk Schadendorf<br />
Deutsches Krebsforschungzentrum (DKFZ)<br />
Heidelberg, Germany<br />
d.schladendorf@dkfz.de<br />
Gustav Gaudernack<br />
Dept. of Immunology<br />
Institute for <strong>Cancer</strong> <strong>Research</strong><br />
The Norwegian Radium Hospital<br />
Oslo, Norway<br />
gustav.gaudemack@labmed.uio.no<br />
Graham Ball<br />
Loreus Ltd<br />
Nottingham Trent University<br />
Nottingham, United Kingdom<br />
graham.balls@ntu.ac.uk<br />
Project number<br />
LSHC-CT-2004-503306<br />
EC contribution<br />
€ 4 166 513<br />
Duration<br />
42 months<br />
Starting date<br />
01/01/2005<br />
Instrument<br />
STREP<br />
Project website<br />
www.enactcancer<br />
research.org<br />
Costas Baxevanis<br />
Dept. of Immunology<br />
Hellenic Anticancer Institute<br />
Athens, Greece<br />
Anthony Walker<br />
Onyvax Ltd<br />
St George’s Hospital Medical School<br />
London, United Kingdom<br />
Italo Dodi<br />
School of Science and Technology<br />
Nottingham Trent University<br />
Nottingham, United Kingdom<br />
195
Change language